|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.2485 - 0.3350|
|52 Week Range||0.2230 - 0.3680|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has entered into a co-development and exclusive licensing agreement with EntheoTech Bioscience Inc. ("EntheoTech" or "ET"), a bioscience company focused on the research and development of formulas and protocols to support opioid tapering and treat chronic pain, depression and other mental health conditions. Under the agree
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its third quarter financial results and operational highlights for the period ended September 30, 2021.
VANCOUVER, BC / ACCESSWIRE / November 3, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Filament Health, Kidoz Inc., Falcon Gold, Psyched Wellness, Maven Brands Inc.